194 related articles for article (PubMed ID: 11856080)
1. A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis.
Mansfield JC; Giaffer MH; Cann PA; McKenna D; Thornton PC; Holdsworth CD
Aliment Pharmacol Ther; 2002 Jan; 16(1):69-77. PubMed ID: 11856080
[TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of the in vitro prosecretory effects of balsalazide, sulfasalazine, olsalazine, and mesalamine in rabbit distal ileum.
Kles KA; Vavricka SR; Turner JR; Musch MW; Hanauer SB; Chang EB
Inflamm Bowel Dis; 2005 Mar; 11(3):253-7. PubMed ID: 15735431
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
Levine DS; Riff DS; Pruitt R; Wruble L; Koval G; Sales D; Bell JK; Johnson LK
Am J Gastroenterol; 2002 Jun; 97(6):1398-407. PubMed ID: 12094857
[TBL] [Abstract][Full Text] [Related]
4. Oral prolonged release beclomethasone dipropionate and prednisone in the treatment of active ulcerative colitis: results from a double-blind, randomized, parallel group study.
Van Assche G; Manguso F; Zibellini M; Cabriada Nuño JL; Goldis A; Tkachenko E; Varoli G; Kleczkowski D; Annese V; D'Heygere F; Balzano A;
Am J Gastroenterol; 2015 May; 110(5):708-15. PubMed ID: 25869389
[TBL] [Abstract][Full Text] [Related]
5. Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis.
TRUELOVE SC; WATKINSON G; DRAPER G
Br Med J; 1962 Dec; 2(5321):1708-11. PubMed ID: 13994348
[No Abstract] [Full Text] [Related]
6. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Schroeder KW; Tremaine WJ; Ilstrup DM
N Engl J Med; 1987 Dec; 317(26):1625-9. PubMed ID: 3317057
[TBL] [Abstract][Full Text] [Related]
7. Managing Pregnancy and Nursing Affecting African American Women with Inflammatory Bowel Disease: Clinical Outcomes and Parenthood.
M'Koma AE; Ware JN; Nabaweesi RK; Chirwa SS
Med Res Arch; 2023 Jun; 11(6):. PubMed ID: 37492395
[TBL] [Abstract][Full Text] [Related]
8. The Association of Coloproctology of Great Britain and Ireland consensus guidelines in surgery for inflammatory bowel disease.
Brown SR; Fearnhead NS; Faiz OD; Abercrombie JF; Acheson AG; Arnott RG; Clark SK; Clifford S; Davies RJ; Davies MM; Douie WJP; Dunlop MG; Epstein JC; Evans MD; George BD; Guy RJ; Hargest R; Hawthorne AB; Hill J; Hughes GW; Limdi JK; Maxwell-Armstrong CA; O'Connell PR; Pinkney TD; Pipe J; Sagar PM; Singh B; Soop M; Terry H; Torkington J; Verjee A; Walsh CJ; Warusavitarne JH; Williams AB; Williams GL; Wilson RG;
Colorectal Dis; 2018 Dec; 20 Suppl 8():3-117. PubMed ID: 30508274
[TBL] [Abstract][Full Text] [Related]
9. Chronological Review of Endoscopic Indices in Inflammatory Bowel Disease.
Lee JS; Kim ES; Moon W
Clin Endosc; 2019 Mar; 52(2):129-136. PubMed ID: 30130840
[TBL] [Abstract][Full Text] [Related]
10. Golimumab: early experience and medium-term outcomes from two UK tertiary IBD centres.
Samaan MA; Pavlidis P; Digby-Bell J; Johnston EL; Dhillon A; Paramsothy R; Akintimehin AO; Medcalf L; Chung-Faye G; DuBois P; Koumoutsos I; Powell N; Anderson SHC; Sanderson J; Hayee BH; Irving PM
Frontline Gastroenterol; 2018 Jul; 9(3):221-231. PubMed ID: 30047549
[TBL] [Abstract][Full Text] [Related]
11. Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis.
Herfarth H; Barnes EL; Valentine JF; Hanson J; Higgins PDR; Isaacs KL; Jackson S; Osterman MT; Anton K; Ivanova A; Long MD; Martin C; Sandler RS; Abraham B; Cross RK; Dryden G; Fischer M; Harlan W; Levy C; McCabe R; Polyak S; Saha S; Williams E; Yajnik V; Serrano J; Sands BE; Lewis JD;
Gastroenterology; 2018 Oct; 155(4):1098-1108.e9. PubMed ID: 29964043
[TBL] [Abstract][Full Text] [Related]
12. Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.
Narula N; Peerani F; Meserve J; Kochhar G; Chaudrey K; Hartke J; Chilukuri P; Koliani-Pace J; Winters A; Katta L; Shmidt E; Hirten R; Faleck D; Parikh MP; Whitehead D; Boland BS; Singh S; Sagi SV; Fischer M; Chang S; Barocas M; Luo M; Lasch K; Bohm M; Lukin D; Sultan K; Swaminath A; Hudesman D; Gupta N; Shen B; Kane S; Loftus EV; Siegel CA; Sands BE; Colombel JF; Sandborn WJ; Dulai PS
Am J Gastroenterol; 2018 Sep; 113(9):1345. PubMed ID: 29946178
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study.
Kopylov U; Verstockt B; Biedermann L; Sebastian S; Pugliese D; Sonnenberg E; Steinhagen P; Arebi N; Ron Y; Kucharzik T; Roblin X; Ungar B; Shitrit AB; Ardizzone S; Molander P; Coletta M; Peyrin-Biroulet L; Bossuyt P; Avni-Biron I; Tsoukali E; Allocca M; Katsanos K; Raine T; Sipponen T; Fiorino G; Ben-Horin S; Eliakim R; Armuzzi A; Siegmund B; Baumgart DC; Kamperidis N; Maharshak N; Maaser C; Mantzaris G; Yanai H; Christodoulou DK; Dotan I; Ferrante M
Inflamm Bowel Dis; 2018 Oct; 24(11):2442-2451. PubMed ID: 29788318
[TBL] [Abstract][Full Text] [Related]
14. Budesonide Suppositories Are Effective and Safe for Treating Acute Ulcerative Proctitis.
Kruis W; Neshta V; Pesegova M; Alekseeva O; Andreev P; Datsenko O; Levchenko O; Abdulkhakov S; Lozynskyy Y; Mostovoy Y; Soloviev K; Dorofeyev AE; Vieth M; Stiess M; Greinwald R; Mohrbacher R; Siegmund B
Clin Gastroenterol Hepatol; 2019 Jan; 17(1):98-106.e4. PubMed ID: 29702300
[TBL] [Abstract][Full Text] [Related]
15. Zeroing in on endoscopic and histologic mucosal healing to reduce the risk of colorectal neoplasia in inflammatory bowel disease.
Saxena AP; Limdi JK; Farraye FA
Gastrointest Endosc; 2017 Dec; 86(6):1012-1014. PubMed ID: 29146080
[No Abstract] [Full Text] [Related]
16. A multi-centre audit of excess steroid use in 1176 patients with inflammatory bowel disease.
Selinger CP; Parkes GC; Bassi A; Fogden E; Hayee B; Limdi JK; Ludlow H; McLaughlin S; Patel P; Smith M; Raine T
Aliment Pharmacol Ther; 2017 Nov; 46(10):964-973. PubMed ID: 28949018
[TBL] [Abstract][Full Text] [Related]
17. Limited uptake of ulcerative colitis "treat-to-target" recommendations in real-world practice.
Bryant RV; Costello SP; Schoeman S; Sathananthan D; Knight E; Lau SY; Schoeman MN; Mountifield R; Tee D; Travis SPL; Andrews JM
J Gastroenterol Hepatol; 2018 Mar; 33(3):599-607. PubMed ID: 28806471
[TBL] [Abstract][Full Text] [Related]
18. Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review.
Fumery M; Singh S; Dulai PS; Gower-Rousseau C; Peyrin-Biroulet L; Sandborn WJ
Clin Gastroenterol Hepatol; 2018 Mar; 16(3):343-356.e3. PubMed ID: 28625817
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Rectal Tacrolimus for Induction Therapy in Patients With Resistant Ulcerative Proctitis.
Lawrance IC; Baird A; Lightower D; Radford-Smith G; Andrews JM; Connor S
Clin Gastroenterol Hepatol; 2017 Aug; 15(8):1248-1255. PubMed ID: 28286194
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
